Acinetobacter Infections - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 114 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acinetobacter Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Acinetobacter Infections - Pipeline Review, H1 2015', provides an overview of the Acinetobacter Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acinetobacter Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acinetobacter Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acinetobacter Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Acinetobacter Infections Overview 11
Therapeutics Development 12
Pipeline Products for Acinetobacter Infections - Overview 12
Pipeline Products for Acinetobacter Infections - Comparative Analysis 13
Acinetobacter Infections - Therapeutics under Development by Companies 14
Acinetobacter Infections - Therapeutics under Investigation by Universities/Institutes 16
Acinetobacter Infections - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Acinetobacter Infections - Products under Development by Companies 19
Acinetobacter Infections - Products under Investigation by Universities/Institutes 22
Acinetobacter Infections - Companies Involved in Therapeutics Development 23
Achaogen Inc. 23
Adenium Biotech ApS 24
AmpliPhi Biosciences Corporation 25
Aridis Pharmaceuticals LLC 26
AstraZeneca PLC 27
AvidBiotics Corp. 28
ConjuGon, Inc. 29
Emergent BioSolutions Inc. 30
FAB Pharma 31
LegoChem Biosciences, Inc 32
Melinta Therapeutics, Inc 33
Microbiotix, Inc. 34
Northern Antibiotics Oy 35
Nosopharm SAS 36
Novan, Inc. 37
Omnia Molecular Ltd. 38
Pfizer Inc. 39
Phylogica Limited 40
Sarepta Therapeutics, Inc. 41
Sealife PHARMA GMBH 42
Shionogi & Co., Ltd. 43
Synthetic Biologics, Inc. 44
Techulon, Inc. 45
Trana Discovery, Inc. 46
Vaxdyn, S.L. 47
Acinetobacter Infections - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Target 50
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
A-3APO - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AA-139 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ACHN-975 Prodrug - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Antisense Oligonucleotide for Acinetobacter Baumannii Infections - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AR-401 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Biologics for Acinetobacter Baumanii - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BXN-112 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
EV-035 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Fab-001 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
GN-4474 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LCB-100200 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MBX-1162 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MDN-0057 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
MDN-0058 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
MDN-0059 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MDN-0060 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
NAB-7061 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
NAB-739 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
NAB-741 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
NOSO-95300 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
NVN-1000 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
NVN-4428 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
RX-05 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RXP-873 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
S-649266 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
SLP-0905 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule for Acinetobacter baumannii Infections - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Gram-Negative Bacterial Infections - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Small Molecules to Inhibit Tryptophanyl-tRNA synthetase for Bacterial Infections - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
SYN-001 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
VXD-001 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
VXD-003 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Acinetobacter Infections - Recent Pipeline Updates 108
Acinetobacter Infections - Dormant Projects 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables

Number of Products under Development for Acinetobacter Infections, H1 2015 12
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Acinetobacter Infections - Pipeline by Achaogen Inc., H1 2015 23
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2015 24
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2015 25
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015 26
Acinetobacter Infections - Pipeline by AstraZeneca PLC, H1 2015 27
Acinetobacter Infections - Pipeline by AvidBiotics Corp., H1 2015 28
Acinetobacter Infections - Pipeline by ConjuGon, Inc., H1 2015 29
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H1 2015 30
Acinetobacter Infections - Pipeline by FAB Pharma, H1 2015 31
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 32
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 33
Acinetobacter Infections - Pipeline by Microbiotix, Inc., H1 2015 34
Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H1 2015 35
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2015 36
Acinetobacter Infections - Pipeline by Novan, Inc., H1 2015 37
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H1 2015 38
Acinetobacter Infections - Pipeline by Pfizer Inc., H1 2015 39
Acinetobacter Infections - Pipeline by Phylogica Limited, H1 2015 40
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 41
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2015 42
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 43
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H1 2015 44
Acinetobacter Infections - Pipeline by Techulon, Inc., H1 2015 45
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H1 2015 46
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H1 2015 47
Assessment by Monotherapy Products, H1 2015 48
Assessment by Combination Products, H1 2015 49
Number of Products by Stage and Target, H1 2015 51
Number of Products by Stage and Mechanism of Action, H1 2015 53
Number of Products by Stage and Route of Administration, H1 2015 55
Number of Products by Stage and Molecule Type, H1 2015 57
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H1 2015 108
Acinetobacter Infections - Dormant Projects, H1 2015 112